AnaptysBio Completes Spin-Off of First Tracks Biotherapeutics: Detailed Financial Impact and Key Shareholder Insights

Overview of the Spin-Off Transaction

On April 20, 2026, AnaptysBio, Inc. finalized the separation of its biopharmaceutical operations through a spin-off, creating a new, independent public company named First Tracks Biotherapeutics, Inc.. This transaction marks a significant structural change for AnaptysBio, potentially reshaping its operational and financial landscape.

Key Points and Financial Highlights

• Spin-Off Date: April 20, 2026. AnaptysBio completed the spin-off of its biopharma operations into First Tracks Biotherapeutics, which is now an independent, publicly traded company.
• Financial Reporting: All relevant historical financials for AnaptysBio have been restated to reflect First Tracks as discontinued operations for the years ended December 31, 2023, 2024, and 2025.
• Initial Cash Distribution: AnaptysBio provided an initial cash distribution of \$100 million to First Tracks Biotherapeutics as part of the spin-off transaction.
• Non-Recurring Spin-Off Costs: AnaptysBio expects to incur approximately \$7 million in additional non-recurring costs related to the spin-off, including transaction advisory and professional fees, to be expensed within 12 months following the spin-off.
• Transition Services Agreement: AnaptysBio and First Tracks entered into a transition services agreement, under which First Tracks will provide certain post-closing services to AnaptysBio on a transitional basis. A pro forma adjustment of approximately \$2 million has been recorded as an increase to selling, general, and administrative expenses.
• Tax Impact: The pro forma adjustments include an income tax expense based on an estimated 25% combined federal and state tax rate on 2025 net income (excluding the impact of available net operating losses and R&D credits).

Detailed Pro Forma Financials – Key Figures

Balance Sheet Impact (as of December 31, 2025)

• Cash and Cash Equivalents: Decreased from \$238.2 million to \$138.2 million after a \$100 million distribution to First Tracks.
• Total Assets: Dropped from \$364.4 million to \$258.3 million post-spin-off.
• Accrued Expenses: Increased from \$32.7 million to \$80 million due to anticipated spin-off costs.
• Total Stockholders’ Equity: Swung from \$37.2 million to negative \$116.3 million after the spin-off and related adjustments, mainly due to the cash distribution and additional expenses.

Income Statement Impact (Year Ended December 31, 2025)

• Collaboration Revenue: Unchanged at \$234.6 million, as revenues from First Tracks are now reclassified as discontinued operations.
• Total Operating Expenses: Dramatically reduced from \$186.7 million to \$16.7 million after reclassification and adjustments.
• Net Income: AnaptysBio swings to a pro forma net income of \$114.9 million from a historical net loss of \$13.2 million due to the exclusion of First Tracks operations and one-time transaction accounting adjustments.
• Net Income Per Share (2025): Basic and diluted pro forma net income per share is \$3.99 and \$3.07, respectively, compared to a historical loss per share of \$(0.46).

Price-Sensitive and Shareholder-Relevant Issues

• Significant Change in Capital Structure: The \$100 million reduction in cash and negative equity position post-spin-off are critical developments for current and prospective shareholders. The negative equity could impact the company’s ability to raise capital or its attractiveness to investors.
• Expense Management: Shareholders should note the anticipated \$7 million in non-recurring costs and the \$2 million increase in administrative expenses related to transitional services. These may affect short-term profitability and cash flows.
• Strategic Refocus: With First Tracks spun off, AnaptysBio will focus solely on its continuing operations, which may lead to a reevaluation of its business model and growth prospects. Investors should monitor management’s strategic communications closely for future plans.
• Tax Implications: The pro forma results include a significant tax expense adjustment for 2025, which could affect net earnings and, consequently, valuation multiples.
• Potential Volatility: The transition to a streamlined business model and the financial adjustments may result in increased share price volatility as the market digests the new standalone profile of both AnaptysBio and First Tracks.

Forward-Looking Considerations

• The pro forma financials are based on current information and assumptions. Actual results may vary, especially as AnaptysBio executes on its post-spin-off strategy and manages its new capital structure.
• Investors should review both AnaptysBio’s and First Tracks’ separate filings for updated guidance, business outlook, and risk disclosures.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. The information is based on unaudited pro forma financials and forward-looking statements which are subject to change. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. AnaptysBio’s actual results may differ materially from the pro forma projections presented here.

View ANAPTYSBIO, INC Historical chart here